Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/1/138 |
id |
doaj-cd77ceade10e4683b7d74e70f060dee7 |
---|---|
record_format |
Article |
spelling |
doaj-cd77ceade10e4683b7d74e70f060dee72021-01-19T00:04:43ZengMDPI AGDiagnostics2075-44182021-01-011113813810.3390/diagnostics11010138Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?Matteo Santoni0Francesco Massari1Sergio Bracarda2Giuseppe Procopio3Michele Milella4Ugo De Giorgi5Umberto Basso6Gaetano Aurilio7Lorena Incorvaia8Angelo Martignetti9Mimma Rizzo10Giacomo Cartenì11Enrique Grande12Marc R. Matrana13Simon J. Crabb14Nuno Vau15Giulia Sorgentoni16Alessia Cimadamore17Rodolfo Montironi18Nicola Battelli19Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100 Macerata, ItalyDivision of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, ItalyMedical and Translational Oncology Unit, Department of Oncology, AziendaOspedaliera Santa Maria, 05100 Terni, ItalyDepartment of Medical Oncology, Istituto Nazionale dei Tumori IRCCS, 20133 Milan, ItalySection of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust (AOUI Verona), P.le L.A. Scuro 10, 37134 Verona, ItalyDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, ItalyDepartment of Medical Oncology, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, ItalyMedical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, 90127 Palermo, ItalyDipartimento Oncologico Usl Sud-est Toscana-Area Senese, Località Campostaggia s.n.c., 53036 Poggibonsi, ItalyDivision of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri 27100 Pavia, ItalyDepartment of Medical Oncology, AO “A. Cardarelli”, 80131 Naples, ItalyDepartment of Medical Oncology, MD Anderson Cancer Center, 28033 Madrid, SpainDepartment of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, 70121 LA, USASouthampton Clinical Trials Unit, University of Southampton, SO16 5AF Southampton, UKUrologic Oncology, Champalimaud Clinical Center, 1400-038 Lisbon, PortugalOncology Unit, Macerata Hospital, via Santa Lucia 2, 62100 Macerata, ItalySection of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, 60126 Ancona, ItalySection of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, 60126 Ancona, ItalyOncology Unit, Macerata Hospital, via Santa Lucia 2, 62100 Macerata, ItalyWe analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan–Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, <i>p</i> < 0.001). The median OS was higher in the BMI ≥ 25 subgroup (30.7 vs. 11.0 months, <i>p </i>= 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, <i>p</i> = 0.029) and OS (39.4 months vs. 11.5 months, <i>p</i> = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC.https://www.mdpi.com/2075-4418/11/1/138body mass indexcabozantinibobesityprognosisreal-world datarenal cell carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matteo Santoni Francesco Massari Sergio Bracarda Giuseppe Procopio Michele Milella Ugo De Giorgi Umberto Basso Gaetano Aurilio Lorena Incorvaia Angelo Martignetti Mimma Rizzo Giacomo Cartenì Enrique Grande Marc R. Matrana Simon J. Crabb Nuno Vau Giulia Sorgentoni Alessia Cimadamore Rodolfo Montironi Nicola Battelli |
spellingShingle |
Matteo Santoni Francesco Massari Sergio Bracarda Giuseppe Procopio Michele Milella Ugo De Giorgi Umberto Basso Gaetano Aurilio Lorena Incorvaia Angelo Martignetti Mimma Rizzo Giacomo Cartenì Enrique Grande Marc R. Matrana Simon J. Crabb Nuno Vau Giulia Sorgentoni Alessia Cimadamore Rodolfo Montironi Nicola Battelli Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics body mass index cabozantinib obesity prognosis real-world data renal cell carcinoma |
author_facet |
Matteo Santoni Francesco Massari Sergio Bracarda Giuseppe Procopio Michele Milella Ugo De Giorgi Umberto Basso Gaetano Aurilio Lorena Incorvaia Angelo Martignetti Mimma Rizzo Giacomo Cartenì Enrique Grande Marc R. Matrana Simon J. Crabb Nuno Vau Giulia Sorgentoni Alessia Cimadamore Rodolfo Montironi Nicola Battelli |
author_sort |
Matteo Santoni |
title |
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? |
title_short |
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? |
title_full |
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? |
title_fullStr |
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? |
title_full_unstemmed |
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? |
title_sort |
body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: a new prognostic factor? |
publisher |
MDPI AG |
series |
Diagnostics |
issn |
2075-4418 |
publishDate |
2021-01-01 |
description |
We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan–Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, <i>p</i> < 0.001). The median OS was higher in the BMI ≥ 25 subgroup (30.7 vs. 11.0 months, <i>p </i>= 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, <i>p</i> = 0.029) and OS (39.4 months vs. 11.5 months, <i>p</i> = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC. |
topic |
body mass index cabozantinib obesity prognosis real-world data renal cell carcinoma |
url |
https://www.mdpi.com/2075-4418/11/1/138 |
work_keys_str_mv |
AT matteosantoni bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT francescomassari bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT sergiobracarda bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT giuseppeprocopio bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT michelemilella bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT ugodegiorgi bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT umbertobasso bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT gaetanoaurilio bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT lorenaincorvaia bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT angelomartignetti bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT mimmarizzo bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT giacomocarteni bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT enriquegrande bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT marcrmatrana bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT simonjcrabb bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT nunovau bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT giuliasorgentoni bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT alessiacimadamore bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT rodolfomontironi bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor AT nicolabattelli bodymassindexinpatientstreatedwithcabozantinibforadvancedrenalcellcarcinomaanewprognosticfactor |
_version_ |
1724332649963585536 |